Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder

Abstract Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Judit Lazary, Monika Elemery, Peter Dome, Szilvia Kiss, Xenia Gonda, Laszlo Tombor, Laszlo Pogany, Gergely Becskereki, Blanka Toth, Gabor Faludi
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4f680e944e1546caa125d4777b86519c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f680e944e1546caa125d4777b86519c
record_format	dspace
spelling	oai:doaj.org-article:4f680e944e1546caa125d4777b86519c2021-12-02T18:27:49ZPeripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder10.1038/s41598-021-87840-52045-2322https://doaj.org/article/4f680e944e1546caa125d4777b86519c2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87840-5https://doaj.org/toc/2045-2322Abstract Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recently published animal data implicated relevant associations with changes in endocannabinoid (eCB) brain levels during rTMS treatment, human studies, however, have not been published. In our study we assessed the detailed phenotypic spectrum of MDD and serum 2-arachidnoylglycerol (2-AG) and anandamide (AEA) levels in 18 patients with treatment-resistant depression before, immediately following, and two weeks after completion of a 10-day rTMS treatment. We found significant associations between serum 2-AG level changes from pretreatment to 2 weeks after treatment and symptom reduction. The greater the increase of 2-AG levels, the greater the improvement of depressive (p = 0.031), anxious (p = 0.007) and anhedonia symptoms (p = 0.047). Here we report for the first time a significant association of human circulating eCB and antidepressant effect of rTMS. Our data may indicate that direct stimulation of targeted brain areas can rapidly alleviate depressive complaints via activation of the eCB system.Judit LazaryMonika ElemeryPeter DomeSzilvia KissXenia GondaLaszlo TomborLaszlo PoganyGergely BecskerekiBlanka TothGabor FaludiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Judit Lazary Monika Elemery Peter Dome Szilvia Kiss Xenia Gonda Laszlo Tombor Laszlo Pogany Gergely Becskereki Blanka Toth Gabor Faludi Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
description	Abstract Repetitive transcranial magnetic stimulation (rTMS) is an effective and well tolerable biological intervention in major depressive disorder (MDD) contributing to rapid symptom improvement. Molecular mechanisms underpinning the therapeutic effects of rTMS have still not been clarified. Recently published animal data implicated relevant associations with changes in endocannabinoid (eCB) brain levels during rTMS treatment, human studies, however, have not been published. In our study we assessed the detailed phenotypic spectrum of MDD and serum 2-arachidnoylglycerol (2-AG) and anandamide (AEA) levels in 18 patients with treatment-resistant depression before, immediately following, and two weeks after completion of a 10-day rTMS treatment. We found significant associations between serum 2-AG level changes from pretreatment to 2 weeks after treatment and symptom reduction. The greater the increase of 2-AG levels, the greater the improvement of depressive (p = 0.031), anxious (p = 0.007) and anhedonia symptoms (p = 0.047). Here we report for the first time a significant association of human circulating eCB and antidepressant effect of rTMS. Our data may indicate that direct stimulation of targeted brain areas can rapidly alleviate depressive complaints via activation of the eCB system.
format	article
author	Judit Lazary Monika Elemery Peter Dome Szilvia Kiss Xenia Gonda Laszlo Tombor Laszlo Pogany Gergely Becskereki Blanka Toth Gabor Faludi
author_facet	Judit Lazary Monika Elemery Peter Dome Szilvia Kiss Xenia Gonda Laszlo Tombor Laszlo Pogany Gergely Becskereki Blanka Toth Gabor Faludi
author_sort	Judit Lazary
title	Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_short	Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_full	Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_fullStr	Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_full_unstemmed	Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder
title_sort	peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rtms) treatment in patients with major depressive disorder
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4f680e944e1546caa125d4777b86519c
work_keys_str_mv	AT juditlazary peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT monikaelemery peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT peterdome peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT szilviakiss peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT xeniagonda peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT laszlotombor peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT laszlopogany peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT gergelybecskereki peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT blankatoth peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder AT gaborfaludi peripheralendocannabinoidserumlevelinassociationwithrepetitivetranscranialmagneticstimulationrtmstreatmentinpatientswithmajordepressivedisorder
_version_	1718377975733288960

Peripheral endocannabinoid serum level in association with repetitive transcranial magnetic stimulation (rTMS) treatment in patients with major depressive disorder

Ejemplares similares